Martsenkovsky 2016.

Methods	16‐week parallel trial of memantine versus placebo
Participants	Inclusion criteria: children 18−36 months old with ASD (based on DSM‐IV criteria) Exclusion criteria: not reported Location/setting: not specifically mentioned but assumed to be in the Ukraine Sample size: 76 Number of withdrawals/dropouts Gender: not reported Mean age: 18‐36 months of age IQ: not reported Baseline ABC‐I or other BoC: unknown Concomitant medications: not reported History of previous medications: not reported
Interventions	Intervention (memantine) for 16 weeks: maximum of 15 mg/day (mean daily dose of 7.5 mg/day for children 18‐25 months, 10.3 mg/day for children 26‐36 months) Comparator (placebo) for 16 weeks: equivalent placebo
Outcomes	Primary outcomes: AEs ABC (subscales unknown or if the measure is the Aberrant Behaviour Checklist or a different ABC scale)
Notes	Study start date: details not reported Study end date: details not reported Source of funding: details not reported Conflicts of interest: details not reported Comments: only F values provided